ENDRA Life Sciences Inc.
NDRA
$4.09
-$0.0519-1.25%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.19% | -74.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.45% | -65.80% | |||
| Operating Income | 11.45% | 65.80% | |||
| Income Before Tax | -18.30% | 75.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -18.30% | 75.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -18.30% | 75.02% | |||
| EBIT | 11.45% | 65.80% | |||
| EBITDA | 11.25% | 66.04% | |||
| EPS Basic | 8.02% | 75.83% | |||
| Normalized Basic EPS | 8.01% | 75.83% | |||
| EPS Diluted | 8.02% | 75.83% | |||
| Normalized Diluted EPS | 8.01% | 75.83% | |||
| Average Basic Shares Outstanding | 28.60% | 3.34% | |||
| Average Diluted Shares Outstanding | 28.60% | 3.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||